Investors + Media
AveXis, Inc. is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality, and for the treatment of SMA Type 2. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1 and Type 2, we also plan to develop other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene.
AveXis Enters into Licensing Agreement with Genethon
AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results
|There are currently no events scheduled.|
Sign up to receive e-mail alerts whenever AveXis, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Vice President, Investor Relations and Corporate Communications
Phone: (650) 862-4134
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|